Fairvalue-Calculator Fairvalue-Calculator

Uniphar plc (UPR) Fair Value & Analysis

Healthcare · IE · Market cap €1.3B

Price€4.74
Fair Value€3.71
Upside-21.7%
Quality95/100
Evidence: High Range €1.91 – €5.41

Analysis

Uniphar plc (UPR) currently trades at €4.74, while our model-based Fair Value estimate is €3.71 — implying the stock looks roughly 21.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Uniphar plc, together with its subsidiaries, operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, the Netherlands, and internationally. It operates through three divisions: Uniphar Medtech, Uniphar Pharma, and Uniphar Supply Chain & Retail. The company provides sales, marketing, servicing, quality, compliance, regulatory support, and distribution services to medical device manufacturers; high-value services across the life cycle of a pharmaceutical product; and healthcare professionals with access to medicines that cannot source through traditional channels. It is also involved in the pre-wholesale and wholesale distribution of pharmaceutical, healthcare, and animal health products to pharmacies, hospitals and veterinary surgeons; operates a network of pharmacies under the Life, Allcare, Hickey's, and McCauley brands. In addition, the company provides pharmacy support, pharmaceutical supply chain and services, medical device distribut…

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.